Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspectives in antisense therapeutics

S Agrawal1, R P Iyer

  • 1Hybridon Inc, Cambridge, MA 02139, USA.

Pharmacology & Therapeutics
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of ENT emergencies during the coronavirus disease 2019 pandemic.

The Journal of laryngology and otology·2021
Same author

Acute Primary Tuberculous Ulcer of Glans Penis.

Kathmandu University medical journal (KUMJ)·2020
Same author

Difficulties in developmental follow-up of preterm neonates in a randomised-controlled trial of Bifidobacterium breve M16-V - Experience from Western Australia.

Early human development·2020
Same author

From the Knife to the Endoscope-a History of Bariatric Surgery.

Current obesity reports·2020
Same author

Long-term postnatal outcome of fetuses with prenatally suspected septo-optic dysplasia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2020
Same author

High-resolution imaging of the human incudostapedial joint using synchrotron-radiation phase-contrast imaging.

Journal of microscopy·2020
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
See all related articles

This review covers mixed-backbone oligonucleotides (oligos) as second-generation antisense therapeutics. It examines their pharmacokinetics and toxicology for improved gene expression modulation and therapeutic development.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Development

Background:

  • Oligonucleotides (oligos) are key tools for modulating gene expression in research and therapy.
  • First-generation antisense analogs, oligodeoxynucleoside phosphorothioates, are in clinical trials.
  • Improving in vivo stability, disposition, and pharmacokinetics is crucial for therapeutic oligo development.

Purpose of the Study:

  • To review the pharmacokinetics and toxicology of mixed-backbone oligos.
  • To evaluate second-generation antisense therapeutics for improved properties.
  • To provide an overview of oligo administration routes and their effects.

Main Methods:

  • Review of existing literature on mixed-backbone oligos.
  • Analysis of pharmacokinetic and toxicological data from various administration routes.

Related Experiment Videos

  • Evaluation of chemical modifications for enhanced antisense activity.

    • Main Results:

    • Mixed-backbone oligos represent a second-generation approach to antisense therapeutics.
    • Pharmacokinetics and toxicology vary with administration route (IV, IP, SC, oral).
    • Chemical modifications aim to enhance biological activity and stability.

    Conclusions:

    • Mixed-backbone oligos show promise as advanced antisense therapeutics.
    • Understanding their pharmacokinetic and toxicological profiles is essential for clinical application.
    • Further research into oligo modifications can optimize therapeutic potential.